Rough Sailing for Drug Pricing Reform in Congress

It is unclear whether congressional Democrats will meet their self-appointed deadline to pass and send to President Biden this week a $3.5 trillion economic and social welfare bill including major drug pricing reforms.

340B covered entities worry that language that

Read More »

GOP Senator Files Bill to Preserve Trump’s 340B Insulin/EpiPen Mandate

Sen. John Kennedy (R-La.) has introduced legislation to preserve the Trump administration’s controversial requirement that community health centers pass along all their 340B savings on insulin and EpiPen-like devices to low-income, uninsured, and/or underinsured patients.

A Republican U.S. senator on an important health care spending committee wants Congress to pass a law preserving the Trump administration’s controversial requirement that community health centers pass along all their 340B savings on insulin and EpiPen-like devices to low-income,

Read More »

Hospitals Ask Hill Leaders to Shield 340B, as Vote Nears on Drug Pricing Reform

Hospital groups urged congressional leaders in a Sept. 24 letter to exclude language “that would negatively impact 340B” from major drug pricing reforms that could be voted on this week.

Six national hospital groups late last week urged Democratic and Republican congressional leaders to exclude language “that would negatively impact 340B” from major drug pricing reforms that could be voted on this week.

The American Hospital Association, 340B Health, America’s

Read More »

Janssen Providing Refunds for 340B Overcharges Including Diabetes Drug

Janssen Pharmaceuticals is providing refunds for 340B overcharges on 14 widely used products during the first and second quarters of 2021.

Drug manufacturer Janssen, a Johnson & Johnson company, has notified 340B covered entities they are or might be owed refunds for overcharges on 14 widely used products during the first and second quarters of 2021.

Janssen asked the U.S. Health

Read More »

Seven-Term Senator Grassley, Often Attuned to 340B, Will Run Again in 2022

Sen. Chuck Grassley (R-Iowa), one of the most-engaged members of Congress on 340B matters, is seeking an eighth Senate term.

U.S. Sen. Chuck Grassley (R-Iowa)—one of the most-engaged members of Congress on 340B matters—has announced he will seek an eighth Senate term in next year’s congressional elections.

Grassley, 88, is the Senate’s second-oldest member. (California Democrat Dianne Feinstein, also 88,

Read More »

Judge Rejects Novartis’ Request to Speed Up Hearing in 340B Contract Pharmacy Lawsuit

A federal judge yesterday denied drug maker Novartis’ request to speed up a hearing on its request that the judge block the government from punishing the company over its denials of 340B pricing when health care providers use contract pharmacies

A federal judge yesterday denied drug maker Novartis’ request to speed up a hearing on its request that the judge block the government from punishing the company over its denials of 340B pricing when health care providers use contract pharmacies.

Read More »

News Alert: New Senate Bill Would Let HRSA Audit 340B Providers to See How They Use 340B Net Income

Senator Mike Braun (R-IN) has introduced legislation to let the government audit 340B entities to determine how they use net income from 340B savings.

U.S. Sen. Mike Braun (R-Ind.) introduced legislation last night to let the federal government audit 340B covered entities to determine how they use net income from drugs bought under the 340B program.

Braun filed the bill late yesterday. According

Read More »

Starting Next Month, HRSA Plans to Audit Some 340B Entities Onsite for First Time Since Pandemic

HRSA says it may resume some onsite audits of 340B covered entities as early as next month, sparking concerns among some providers already battling the fallout from the Delta variant of COVID-19.

The U.S. Health Resources and Services Administration (HRSA) says it plans to resume some onsite 340B compliance audits of covered entities starting in October. This is sparking concern among 340B providers in light of crisis conditions in some states fueled

Read More »

House GOP Conference Chair Stefanik Signs on to 340B Anti-Pickpocketing Bill

House Republican conference chair Elise Stefanik (R-NY) is the most high profile sponsor of date for the bipartisan 340B Protect Act.

U.S. House GOP Conference Chair Elise Stefanik (N.Y.), the third highest-ranking House Republican, has issued a news release and tweeted about signing on as a sponsor of bipartisan legislation prohibiting pharmacy benefit managers (PBMs) and other third-party payers from paying

Read More »

HHS Is Vetting OPA Director Applications and Apexus Is Seeking a New Senior VP For High-Profile Position

HRSA and its 340B government contractor are looking to fill two critically important positions including replacing Rear Admiral Krista Pedley who has recently been promoted from her position as OPA Director.

The federal government has started reviewing applications from individuals seeking to be the next Director of the U.S. Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA), the unit within HRSA that oversees the 340B program. Tuesday, Sept.

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live